Effect of α+-thalassaemia on episodes of fever due to malaria and other causes: a community-based cohort study in Tanzania
© Veenemans et al; licensee BioMed Central Ltd. 2011
Received: 16 April 2011
Accepted: 22 September 2011
Published: 22 September 2011
It is controversial to what degree α+-thalassaemia protects against episodes of uncomplicated malaria and febrile disease due to infections other than Plasmodium.
In Tanzania, in children aged 6-60 months and height-for-age z-score < -1.5 SD (n = 612), rates of fevers due to malaria and other causes were compared between those with heterozygous or homozygotes α+-thalassaemia and those with a normal genotype, using Cox regression models that accounted for multiple events per child.
The overall incidence of malaria was 3.0/child-year (1, 572/526 child-years); no differences were found in malaria rates between genotypes (hazard ratios, 95% CI: 0.93, 0.82-1.06 and 0.91, 0.73-1.14 for heterozygotes and homozygotes respectively, adjusted for baseline factors that were predictive for outcome). However, this association strongly depended on age: among children aged 6-17 months, those with α+-thalassaemia experienced episodes more frequently than those with a normal genotype (1.30, 1.02-1.65 and 1.15, 0.80-1.65 for heterozygotes and homozygotes respectively), whereas among their peers aged 18-60 months, α+-thalassaemia protected against malaria (0.80, 0.68-0.95 and 0.78, 0.60-1.03; p-value for interaction 0.001 and 0.10 for hetero- and homozygotes respectively). No effect was observed on non-malarial febrile episodes.
In this population, the association between α+-thalassaemia and malaria depends on age. Our data suggest that protection by α+-thalassaemia is conferred by more efficient acquisition of malaria-specific immunity.
Alpha+-thalassaemia is a common genetic trait in malaria-endemic areas in sub-Saharan Africa, Asia and Melanesia, and may protect against the decline in haemoglobin concentration that is associated with asymptomatic Plasmodium infection .
Case-control studies [2–4] and two cohort studies [5, 6] have consistently shown that α+-thalassaemia is associated with reduced risks of severe malaria. Reports on its effect on uncomplicated malaria are inconsistent. A study in Vanuatu showed that, among children aged < 5 years, homozygous (but not heterozygous) α+-thalassaemia was associated with an increased incidence of uncomplicated malaria due to both Plasmodium vivax and Plasmodium falciparum (incidence ratio, 95% CI: 2.2, 1.3-2.7 and 1.6, 1.0-2.6, respectively); paradoxically, among children aged 5-9 years, there was no evidence of such an association . Subsequent studies in Africa found no effect [6, 8, 9] or protection  by α+-thalassaemia against uncomplicated malaria due to P. falciparum.
In a prospective case-control study in Papua New Guinean children, α+-thalassaemia was also strongly protective against hospitalization for disease episodes caused by infections other than malaria .
In this study among preschool children, it was aimed to assess effects of α+-thalassaemia on rates of fevers due to malaria and fever due to other causes, and evaluated to what extent these effects depended on age.
Study area and population
The study was conducted in February 2008-March 2009 in Handeni District, north-eastern Tanzania. The population is a mixture of many different tribes, residing in scattered hamlets, and mainly comprises poor farmer families engaged in subsistence farming. Transmission of malaria (> 95% due to P. falciparum) is intense and perennial, with entomological inoculation rates of 35-400 infectious bites per person-year . Access to primary health care is limited. Artemether-lumefantrine was the first-line treatment for uncomplicated malaria, and available for free only in public care facilities, but not in local shops; accordingly, home treatment with efficacious anti-malarial drugs probably occurred only sporadically.
This prospective cohort study was part of a double-blind randomized trial aimed at measuring the effects of preventive supplementation with zinc and other multi-nutrients on the incidence of malaria. Details about study design will be reported elsewhere. During the follow-up period, children received daily supplements under supervision. Parents were encouraged to bring their children to the research dispensary for fever or other signs of illness.
Ethical approval was provided by the review committees in The Netherlands and Tanzania. Individual written consent was obtained from parents.
Before recruitment (February-August 2008), a census was conducted and all resident children aged < 60 months were registered. Parents and guardians were invited to bring their children for screening. A medical examination was performed by a clinical officer, anthropometric indices were calculated as the average of two recordings taken at consecutive days, and venous blood samples were collected. An aliquot of blood was centrifuged immediately after collection, and a 90 μL red cell pellet including the buffy coat was mixed with 90 μL phosphate-buffered saline and 180 μL of a DNA stabilizing buffer (AS1; Qiagen, Hilden, Germany) and stored at 4°C for subsequent genotyping. Plasma was stored in liquid nitrogen. A second aliquot of whole blood was examined by haematology analyzer (Sysmex KX21, Kobe, Japan) the same day.
Children were eligible for randomization when aged 6-59 months, and with height-for-age z-score < -1.5 SD. Children with weight-for-age z-score < -3 SD, haemoglobin concentration < 70 g/L, signs of severe or chronic disease, those unlikely to comply with interventions, or whose parents/guardians refused consent were excluded. Eligible children were randomly allocated to receive daily supplements with zinc alone, zinc in combination with other micronutrients, micronutrients alone, or placebo. Block randomization was used within six strata defined by Plasmodium infection and age class (6-17 months, 18-35 months and 36-60 months). Children with Plasmodium infection at baseline were treated with artemether-lumefantrine (Novartis Pharma, Basel, Switzerland).
A clinical officer was on 24-h duty at the research clinic. For any child reporting with fever (axillary temperature ≥ 37.5°C) or a history of fever according to the guardian, a finger-prick blood sample was collected to detect the presence of malaria parasites. For all children with a positive dipstick we measured whole blood concentrations of haemoglobin and C-reactive protein. Children were treated free of charge, and referred to the district hospital when indicated.
In samples collected at baseline and from sick children, the presence of parasite-specific lactate dehydrogenase (P. falciparum and other Plasmodium species) was detected by rapid test (CareStart™, Access Bio, Monmouth Jct, USA). This test has a sensitivity of 96% for blood samples with > 50 parasites/μL as determined by microscopy . Blood films were prepared using standard methods. For slides of sick children, parasites were counted against at least 200 leukocytes, and parasite density was calculated assuming 8,000 leukocytes/μL. At least 500 leukocytes were counted before a slide was considered negative. When densities were very high, parasites were counted per 2,000 erythrocytes, with estimates of erythrocyte density based on the haemoglobin concentration measured at the time of the episode, using a linear model based on survey data to describe the relationship between haemoglobin concentration and erythrocyte count.
DNA was isolated from erythrocyte pellets (Qiagen isolation kit); the -α3, 7 deletion type of α+-thalassaemia was determined by polymerase chain reaction . This type of deletion is the most common form of α+-thalassaemia in Africa , with prevalence values often exceeding 50% in eastern Africa [1, 10, 14]; other types of thalassaemia are rare.
Whole-blood concentrations of haemoglobin and C-reactive protein were measured using point-of-care tests (HemoCue, Ängelholm, Sweden and QuikRead, Orion Diagnostica, Espoo, Finland, respectively). Plasma concentrations of C-reactive protein and ferritin for survey samples were measured in The Netherlands (Meander Medical Centre, Amersfoort) on a Beckman Coulter Unicel DxC880i system according to the manufacturer's instructions. Plasma concentrations of P. falciparum- specific histidine-rich protein-2 (HRP2) in samples collected during the first malaria episode were measured using a commercial enzyme-linked immunosorbent assay kit (Malaria Ag Celisa; Cellabs, Brookvale NSW, Australia). This protein is released into the plasma at schizont rupture, and its plasma concentration may more accurately represent total body parasite biomass, because it also reflects the presence of sequestered parasites that remain undetected with conventional microscopy .
Analyses were performed using SPSS (v15·0 for Windows, SPSS, Chicago, IL), CIA (v2.1.2)  and STATA (v11; College Station, Tx). Anthropometric indices were calculated using Epi Info software (version 3.3.2) .
The primary outcome, an episode of malaria, was pre-defined as a guardian-reported history of fever accompanied by either an axillary temperature ≥ 37.5°C or inflammation (whole blood C-reactive protein concentration ≥ 8 g/L), plus a positive result for the pLDH rapid dipstick test. Elevated C-reactive protein concentrations are probably indicative of recent malaria episodes in currently afebrile individuals with parasitaemia [18, 19], and are associated with the severity of malaria (Veenemans and Verhoef, unpublished results). In the primary analysis, a parasite density threshold was not used to define malaria [20, 21] because this can lead to biased estimates of effects when the interventions act by reducing (or increasing) parasite density [22, 23], and density estimates can vary greatly within short time spans, ideally requiring leucocyte counts to be determined simultaneously [24, 25]. To increase specificity of malaria case definitions, Plasmodium-infected participants were treated at baseline to clear parasitaemia before the start of surveillance. Episodes with parasitaemia thresholds of 5,000 and 10,000 parasites/μL were considered as secondary outcomes. Children were presumed to be protected against new malaria infections for 14 days after treatment with artemether-lumefantrine. Recurrent symptoms during this period were assumed to be part of the initial episode and were not counted as separate episodes. Additional outcomes were hospital admissions or death due to infection-related causes (combined end-point), non-malarial febrile episodes (defined as any episode of reported fever that did not classify as malaria, regardless of the presence or absence of parasitaemia, and separated by at least two days), and the severity of malaria episodes as indicated by parasite density, haemoglobin concentrations, concentrations of whole blood C-reactive protein and plasma HRP2.
In the primary analysis, group rates were compared using Cox regression with robust estimates of the standard error to account for multiple episodes within children. It was explored to what extent adjustment for baseline factors that were prognostic for malaria (age class, mosquito net use, Plasmodium infection, distance between homestead and clinic, and height-for-age z-score and micronutrient intervention) influenced the estimates. Because it was anticipated that the effect of α+-thalassemia would depend on age, a stratified analysis was conducted within each of the three age classes used for randomization, and interaction was assessed using a Cox regression model. It was also explored whether there was evidence of an interaction between α+-thalassaemia and the intervention by including interaction terms in the Cox regression model. Incidence and incidence ratios were calculated based on time to first episodes, and Cox regression models were used to obtain adjusted hazard ratios.
Associations between α+-thalassaemia and continuous variables (log-transformed as appropriate to obtain normal distributions) were assessed by ANOVA and multiple linear regression.
Baseline characteristics of study participants and distribution of malaria prognostic factors, by genotype
Sex, M/F [n/n]
33.4 ± 15.9
32.0 ± 15.2
29.9 ± 16.0
Plasmodium infection *
Haemoglobin concentrations, g/L
104.7 ± 12.5
102.2 ± 12.4
94.9 ± 12.8
Without Plasmodium infection
106.7 ± 12.6
104.8 ± 11.6
95.3 ± 13.9
With Plasmodium infection
102.0 ± 11.8
98.8 ± 12.5
94.3 ± 11.3
Mosquito net use ††
-2.38 ± 0.72
-2.43 ± 0.64
-2.63 ± 0.75
Distance from homestead to dispensary, km **
3.56 ± 2.21
3.65 ± 2.28
3.36 ± 1.84
Multi-nutrients without zinc
Multi-nutrients with zinc
Iron deficiency ∥
Without inflammation [n/n] §
Of 2,462 episodes of reported fever, 1,618 had a positive dipstick test result; 1,572 malaria episodes were recorded in 526 child-years of observation. The incidence of malaria was 3.0/child-year; 507 children (83%) experienced at least one malaria episode, recurrent episodes occurred in 395 (63%) of children. The remaining 890 febrile episodes were classified as not being due to malaria; of these, 27 (3%) were associated with a positive result for a malaria dipstick test, but in these cases, fever could not be confirmed and plasma C-reactive protein concentration was < 8 mg/L. The incidence of non-malarial fever cases was 1.69/child-year. Hospital referral for infection-related causes occurred in 68 cases, of which 30 were malaria (19 cases with haemoglobin concentration < 60 g/L, all except one without signs of heart failure or respiratory distress). Malaria incidence decreased with age class (3.73, 3.48 and 2.19 episodes/child-year for age classes 6-17, 18-35 and 36-59 months respectively; p < < 0.001); the corresponding incidence estimates for episodes with haemoglobin concentration < 80 g/L were 0.82, 0.33 and 0.09 episodes/child-year, respectively).
Rates of uncomplicated malaria, non-malarial febrile episodes and severe events (hospital admission or death), by genotype
All episodes of malaria
Hazard ratio, crude
Hazard ratio, adjusted †
Episodes with parasitaemia > 5,000/μL (1,249)
Episodes with parasitaemia > 10,000/μL (1,119)
Episodes with parasitaemia > 100,000/μL (263)
Episodes with haemoglobin concentration < 80 g/L (178)
1 st episodes of malaria
Incidence rate ratio
Hazard ratio, crude
Hazard ratio, adjusted †
All episodes of non-malarial fever
Hazard ratio, crude
Hazard ratio, adjusted ¶
All hospital admissions or deaths §
Hazard ratio, crude
Hazard ratio, adjusted ¶
The rate of episodes with haemoglobin concentrations < 80 g/L was highest among homozygotes and lowest among children with a normal genotype, regardless of age.
The declines in average haemoglobin concentrations between baseline and the first malaria episode were only minor and not substantially different in hetero- or homozygotes (-4.5 g/L and -2.1 g/L) from values observed in children with a normal genotype (-3.0 g/L).
Lastly, the rate of non-malaria febrile episodes was similar between genotypes (Table 2); stratification by age did not indicate differences in age-specific effects.
In this cohort, α+-thalassaemia was associated with increased rates of malaria in children aged < 18 months, but with protection against malaria in older children. There was no evidence that α+-thalassaemia was associated with the severity of malaria episodes as measured by haemoglobin concentrations and other indicators.
Although all Plasmodium-infected children were treated at baseline, the specificity of our case definition may have gradually decreased with time, as more children became asymptomatically infected. Similar results were obtained, however, when restricting the analysis to cases with parasite densities > 10,000/μL or > 100,000/μL. Because these case definitions are more specific for detecting true malaria cases, it is unlikely that a low specificity affected the validity of the conclusions drawn in this report.
Because effect estimates were adjusted for factors associated with malaria risk (including distance to the research facility and intervention), it is unlikely that a difference in external factors (such as intervention, exposure to infection or health seeking behaviour) biased the estimates and would be responsible for the increased risk associated with α+-thalassaemia in the youngest children. It remains unclear however, what mechanism could underlie the increased incidence in the youngest children. It has been put forward that Plasmodium parasites preferentially invade reticulocytes [26, 27]. Thus reticulocytosis, induced by thalassaemia-associated ineffective erythropoiesis, would favour proliferation of Plasmodium parasites . However, there was no strong support that thalassaemia was associated with increased parasite densities in young children, and neither did any previous study. In addition, a recent study found no evidence that reticulocyte counts were increased in individuals with α+-thalassaemia .
Others hypothesized that increased parasite-induced surface expression of neo-antigens on thalassaemic erythrocytes results in enhanced binding of IgG antibody and more rapid clearance of parasitized erythrocytes in the spleen . Clearance in the spleen may be further enhanced by a reduced erythrocyte deformability of thalassaemic cells . In children aged 6-18 months, in whom protection by maternal antibodies has waned, but acquired immunity is still low and parasite replication only partly restrained by an effective circulating antibody repertoire, such increased antigen presentation in the spleen may result in a more rapid development of symptoms, and at the same time a more efficient and more rapid acquisition of protective immunity. Further evidence to support this theory is, however, lacking.
Nevertheless, the findings reported here contribute to existing epidemiological evidence that predisposition to malaria due to P. falciparum in both heterozygotes and homozygotes for α+-thalassaemia early in life may result in protection against severe malaria, and (at older age) uncomplicated malaria due to the same species. In Vanuatu, the incidence of malaria due to P. falciparum and P. vivax was increased in children aged < 5 years with homozygous α+-thalassaemia relative to children with normal genotype , but the study found no evidence of protection among either hetero- or homozygotes in children aged 5-9 years. Contrary to our findings, the incidence in heterozygotes and children with normal genotype were similar, regardless of whether the analysis was stratified by age or not. The estimates in the current report are more precise, however, due to the larger number of malaria cases in this study (622 and 812 in children with heterozygote and normal genotypes, respectively, versus 159 and 304 in Vanuatu). In an area adjacent that used in the current report, with similar levels of malaria endemicity, α+-thalassaemia was found to be associated with protection against malaria in children aged 6 months to 20 years . This protection seemed more pronounced among children aged > 5 years, but the analysis was based on 50 episodes (41 among children aged < 5 years) and had insufficient precision to adequately assess age-specific effects in early life.
Because the intensity of malaria exposure determines how fast protective immunity is obtained, the age at which a difference in protective immunity between children with and without α+-thalassaemia becomes evident shall vary with transmission intensity. This may at least in part explain differences between studies; under conditions of intense transmission, such as in the present study, the difference attained would become evident earlier in life than in conditions of less intense transmission such as encountered in Vanuatu .
The finding that α+-thalassaemia is associated with an increased frequency of malaria in children aged 6-18 months may seem to contradict reports from hospital-based studies that α+-thalassaemia protects against severe malarial anaemia [4, 6], which has the highest incidence in the same age range . An increased fever rate may, however, not necessarily translate to an increased risk of severe malaria anaemia if the decline in haemoglobin during these attacks is halted or sufficiently slowed down to before reaching a critical level that leads to admission. A potential mechanism for such phenomenon has recently been proposed . In thalassaemia, the total amount of haemoglobin is divided over erythrocytes that are disproportionately increased in numbers but reduced in size and haemoglobin content. Thus, an equal proportion of erythrocytes being destroyed by malaria parasites results in a smaller haemoglobin reduction in individuals with α+-thalassaemia than in their peers with normal genotype.
When analysing the decline in haemoglobin concentration between baseline and first malaria episode, we did not find evidence of such protection. It should be noted, however, that the average decline in haemoglobin concentration during malaria episodes was relatively small, and that very few (19) episodes occurred whereby haemoglobin concentrations dropped below 60 g/L. This is probably due to good access to treatment in our study, and haematological gains due to the nutrient interventions. By contrast, in a pilot survey in the same area in 2006, children with α+-thalassaemia were found to be protected against the decline in haemoglobin concentration associated with mild and asymptomatic infections . At that time, there were no first-line health facilities in the area, and artemether-lumefantrine was not available through public facilities. Thus this setting was probably better comparable to the circumstances under which α+-thalassaemia has been providing a survival advantage in the past.
A likely explanation for the increased rates of episodes with haemoglobin concentrations < 80 g/L observed in heterozygotes and homozygotes (Table 2) is that children with these genotypes had lower initial haemoglobin concentrations before the onset of malaria episodes than children with normal genotype. Thus a reduction in haemoglobin concentration caused by malaria in heterozygotes and homozygotes will more readily result in haemoglobin concentrations dropping below a threshold of 80 g/L.
In pre-school Tanzanian children living in an area of intense transmission, and with height-for-age z-score < -1.5 SD, effects of α+-thalassaemia on malaria rates were age-dependent: it was associated with increased rates in children aged < 18 months as opposed to decreased rates in older children. There was no evidence that α+-thalassaemia was associated with the severity of malaria episodes.
Acknowledgements and funding
We thank participants, volunteers, staff, students and Tanzanian colleagues for support. This work was supported by WOTRO Science for Global Development [grant numbers W93-413, WAO93-441, WIZ93-465]; UNICEF; Cornelis Visser Foundation and Wageningen University (INREF).
- Veenemans J, Andang'o PEA, Mbugi EV, Kraaijenhagen RJ, Mwaniki DL, Mockenhaupt FP, Roewer S, Olomi RM, Shao JF, Van der Meer JWM, Savelkoul HFJ, Verhoef H: α+-thalassemia protects against anemia associated with asymptomatic malaria: evidence from community-based surveys in Kenya and Tanzania. J Infect Dis. 2008, 198: 401-408. 10.1086/589884.View ArticlePubMed
- Allen SJ, O'Donnell A, Alexander ND, Alpers MP, Peto TEA, Clegg JB, Weatherall DJ: Alpha+-thalassemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci USA. 1997, 94: 14736-14741. 10.1073/pnas.94.26.14736.PubMed CentralView ArticlePubMed
- Mockenhaupt FP, Ehrhardt S, Gellert S, Otchwemah RN, Dietz E, Anemana SD, Bienzle U: Alpha+-thalassemia protects African children from severe malaria. Blood. 2004, 104: 2003-2006. 10.1182/blood-2003-11-4090.View ArticlePubMed
- May J, Evans JA, Timmann C, Ehmen C, Busch W, Thye T, Agbenyega T, Horstmann RD: Hemoglobin variants and disease manifestations in severe falciparum malaria. JAMA. 2007, 297: 2220-2226. 10.1001/jama.297.20.2220.View ArticlePubMed
- Williams TN, Wambua S, Uyoga S, Macharia A, Mwacharo JK, Newton CRJC, Maitland K: Both heterozygous and homozygous alpha+ thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood. 2005, 106: 368-371. 10.1182/blood-2005-01-0313.View ArticlePubMed
- Wambua S, Mwangi TW, Kortok M, Uyoga SM, Macharia AW, Mwacharo JK, Weatherall DJ, Snow RW, Marsh K, Williams TN: The effect of α+-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. PLoS Med. 2006, 3: e158-10.1371/journal.pmed.0030158.PubMed CentralView ArticlePubMed
- Williams TN, Maitland K, Bennett S, Ganczakowski M, Peto TEA, Newbold CI, Bowden DK, Weatherall DJ, Clegg JB: High incidence of malaria in alpha-thalassaemic children. Nature. 1996, 383: 522-525. 10.1038/383522a0.View ArticlePubMed
- Allen SJ, Rowe P, Allsopp CEM, Riley EM, Jakobsen PH, Hill AVS, Greenwood BM: A prospective study of the influence of α+-thalassaemia on morbidity from malaria and immune responses to defined Plasmodium falciparum antigens in Gambian children. Trans R Soc Trop Med Hyg. 1993, 87: 282-285. 10.1016/0035-9203(93)90129-E.View ArticlePubMed
- Williams TN, Mwangi TW, Wambua S, Peto TEA, Weatherall DJ, Gupta S, Recker M, Penman BS, Uyoga S, Macharia A, Mwacharo JK, Snow RW, Marsh K: Negative epistasis between the malaria-protective effects of α+-thalassemia and the sickle cell trait. Nat Genet. 2005, 37: 1253-1257. 10.1038/ng1660.PubMed CentralView ArticlePubMed
- Enevold A, Lusingu JP, Mmbando B, Alifrangis M, Lemnge MM, Bygbjerg IC, Theander TG, Vestergaard LS: Reduced risk of uncomplicated malaria episodes in children with alpha-thalassemia in Northeastern Tanzania. Am J Trop Med Hyg. 2008, 78: 714-720.PubMed
- Ellman R, Maxwell C, Finch R, Shayo D: Malaria and anaemia at different altitudes in the Muheza district of Tanzania: childhood morbidity in relation to level of exposure to infection. Ann Trop Med Parasitol. 1998, 92: 741-753. 10.1080/00034989858989.View ArticlePubMed
- Piper R, Lebras J, Wentworth L, Hunt-Cooke A, Houzé S, Chiodini P, Makler M: Immunocapture diagnostic assays for malaria using Plasmodium lactate dehydrogenase (pLDH). Am J Trop Med Hyg. 1999, 60: 109-118.PubMed
- Liu YT, Old JM, Miles K, Fisher CA, Weatherall DJ, Clegg JB: Rapid detection of alpha-thalassaemia deletions and alpha-globin gene triplication by multiplex polymerase chain reactions. Br J Haematol. 2000, 108: 295-299. 10.1046/j.1365-2141.2000.01870.x.View ArticlePubMed
- Williams TN: Human red blood cell polymorphisms and malaria. Curr Opin Microbiol. 2006, 9: 388-94. 10.1016/j.mib.2006.06.009.View ArticlePubMed
- Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut K, Chotivanich K, Newton PN, Pitisuttithum P, Smithyman AM, White NJ, Day NPJ: Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med. 2005, 2: 788-795.
- Altman DG, Machin D, Bryant TN, Gardner MJ, eds: Statistics with confidence: confidence intervals and statistical guidelines. 2000, London, UK: BMJ Books
- Accessed 30 August 2011, [http://www.cdc.gov/epiinfo]
- Hurt N, Smith T, Teuscher T, Tanner M: Do high levels of c-reactive protein in tanzanian children indicate malaria morbidity?. Clin Diagn Lab Immunol. 1994, 1: 437-444.PubMed CentralPubMed
- Hurt N, Smith T, Tanner M, Mwankusye S, Bordmann G, Weiss NA, Teuscher T: Evaluation of C-reactive protein and haptoglobin as malaria episode markers in an area of high transmission in Africa. Trans R Soc Trop Med Hyg. 1994, 88: 182-186. 10.1016/0035-9203(94)90287-9.View ArticlePubMed
- Schellenberg JRM, Smith T, Alonso PL, Hayes RJ: What is clinical malaria? Finding case definitions for field research in highly endemic areas. Parasitol Today. 1994, 10: 439-442. 10.1016/0169-4758(94)90179-1.View ArticlePubMed
- Smith T, Schellenberg JA, Hayes R: Attributable fraction estimates and case definitions for malaria in endemic areas. Stat Med. 1994, 13: 2345-2358. 10.1002/sim.4780132206.View ArticlePubMed
- O'Meara WP, Hall BF, McKenzie FE: Malaria vaccine efficacy: the difficulty of detecting and diagnosing malaria. Malaria J. 2007, 6: 36-10.1186/1475-2875-6-36.View Article
- Smith TA: Measures of clinical malaria in field trials of interventions against Plasmodium falciparum. Malar J. 2007, 6: 53-10.1186/1475-2875-6-53.PubMed CentralView ArticlePubMed
- Koram KA, Molyneux ME: When is "malaria" malaria? The different burdens of malaria infection, malaria disease, and malaria-like illnesses. Am J Trop Med Hyg. 2007, 77 (Suppl 6): 1-5.PubMed
- Delley V, Bouvier P, Breslow N, Doumbo O, Sagara I, Diakite M, Mauris A, Dolo A, Rougemont A: What does a single determination of malaria parasite density mean? A longitudinal survey in Mali. Trop Med Int Health. 2000, 5: 404-412. 10.1046/j.1365-3156.2000.00566.x.View ArticlePubMed
- Pasvol G, Weatherall DJ, Wilson RJ: The increased susceptibility of young red cells to invasion by the malarial parasite Plasmodium falciparum. Br J Haematol. 1980, 45: 285-95. 10.1111/j.1365-2141.1980.tb07148.x.View ArticlePubMed
- Pasvol G, Wilson RJ: The interaction of malaria parasites with red blood cells. Br Med Bull. 1982, 38: 133-40.PubMed
- Weatherall DJ, Clegg JB: The thalassaemia syndromes. 2001, Oxford, UK: Blackwell Science, 4View Article
- Krugner F, Zaccariotto TR, Rosim ET, Costa FF, Grotto HZ, Sonati MF: Reticulocyte evaluation in α+-thalassemia. Am J Hematol. 2006, 81: 68-70. 10.1002/ajh.20487.View ArticlePubMed
- Luzzi GA, Merry AH, Newbold CI, Marsh K, Pasvol G: Protection by alpha-thalassaemia against Plasmodium falciparum malaria: modified surface antigen expression rather than impaired growth or cytoadherence. Immunol Lett. 1991, 30: 233-240. 10.1016/0165-2478(91)90031-5.View ArticlePubMed
- Dondorp AM, Chotivanich KT, Fucharoen S, Silamut K, Vreeken J, Kager PA, White NJ: Red cell deformability, splenic function and anemia in thalassemia. Brit J Haem. 1999, 105: 505-508. 10.1111/j.1365-2141.1999.01367.x.View Article
- Snow RW, Omumbo JA, Lowe B, Molyneux CS, Obiero J-O, Palmer A, Weber MW, Pinder M, Nahlen B, Obonyo C, Newbold C, Gupta S, Marsh K: Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet. 1997, 349: 1650-1654. 10.1016/S0140-6736(97)02038-2.View ArticlePubMed
- Fowkes FJI, Allen SJ, Allen A, Alpers MP, Weatherall DJ, Day KP: Increased microerythrocyte count in homozygous α+-thalassaemia contributes to protection against severe malarial anaemia. PLoS Med. 2008, 5: 494-501.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.